Abstract
Hantaviruses, part of the Bunyaviridae family, are a genus of negative-sense, single-stranded RNA viruses that cause two major diseases: New-World Hantavirus Cardiopulmonary Syndrome and Old-World Hemorrhagic Fever with Renal Syndrome. Hantaviruses generally are found worldwide with each disease corresponding to their respective hemispheres. New-World Hantaviruses spread by specific rodent-host reservoirs and are categorized as emerging viruses that pose a threat to global health and security due to their high mortality rate and ease of transmission. Incidentally, reports of Hantavirus categorization as a bioweapon are often contradicted as both US National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention refer to them as Category A and C bioagents respectively, each retaining qualitative levels of importance and severity. Concerns of Hantavirus being engineered into a novel bioagent has been thwarted by Hantaviruses being difficult to culture, isolate, and purify limiting its ability to be weaponized. However, the natural properties of Hantaviruses pose a threat that can be exploited by conventional and unconventional forces. This review seeks to clarify the categorization of Hantaviruses as a bioweapon, whilst defining the practicality of employing New-World Hantaviruses and their effect on armies, infrastructure, and civilian targets.
Introduction
Hantaviruses are emerging zoonotic viruses that are responsible for two human diseases: Hantavirus Cardiopulmonary Syndrome (HCPS) associated with New-World Hantaviruses found in the western hemisphere; and Hemorrhagic Fever with Renal Syndrome (HFRS) associated with Old-World Hantaviruses in the eastern hemisphere (Mittler et al., 2019). Collectively, 150,000 – 200,000 cases of hantavirus disease are reported annually with the majority of HFRS cases occurring in Asia, specifically in the People’s Republic of China which constitutes upwards of 90% of cases (Schmaljohn, 2009; ; Liu et al., 2019). HCPS, comparatively, presents a stark minority in annual cases, roughly 300, with the majority of cases being in South America and primarily Brazil (Watson et al., 2014; ). The annual average cases of New-World HCPS-causing hantaviruses in the western hemisphere are summarized in Figure 1. Both HFRS and HCPS exhibit drastically different mortality rates, with the former causing upwards of 12% while the latter inflicting upwards of 35–50% mortality on infected persons (; Llah et al., 2018). Due to hantaviruses being emerging pathogens with HCPS-causing infections retaining a high mortality rate, there remains a possible risk of hantaviruses being engineered into novel bioweapons (Meyer and Morse, 2008; Kruger et al., 2011; Williams and Sizemore, 2020).
FIGURE 1
Biological systems that can potentially be used as weapons have been divided into three groups designated Category A, B, and C (Table 1) (
TABLE 1
| Category | Category definition | Diseases | Organisms and agents |
| A | High-priority agents that include organisms that pose a risk to national security because they: • Can be easily disseminated or transmitted person-to-person • Result in high mortality and have the potential to cause a major public health impact • Might cause public panic and social disruption • Require special action for public health preparedness | Anthrax Botulism Plague Smallpox Tularemia Viral Hemorrhagic Fevers (VHFs) | Bacillus anthracis Clostridium botulinum toxin Yersinia pestis Variola major Francisella tularensis Filoviruses (Ebola, Marburg) Arenaviruses (Lassa, Machupo) |
| B | Second highest priority agents which include those that: • Are moderately easy to disseminate • Result in moderate morbidity rates and low mortality • Require specific enhancements of laboratory capacity and enhanced disease surveillance | Brucellosis Epsilon Toxin Food Safety Threats Glanders Melioidosis Psittacosis Q Fever Ricin Toxin Staphylococcal Enterotoxin B Typhus Fever Viral Encephalitis Water Safety Threats | Brucella species Clostridium perfringens Salmonella species Escherichia coli O157:H7 Shigella Burkholderia mallei Burkholderia pseudomallei Chlamydia psittaci Coxiella burnetii Ricinus communis (Castor beans) Staphylococcus aureus Rickettsia prowazekii Alphaviruses (Venezuelan Equine Encephalitis, Eastern Equine Encephalitis, Western Equine Encephalitis) Vibrio cholerae Cryptosporidium parvum |
| C | Third highest priority agents include emerging pathogens that could be engineered for mass dissemination in the future because of: • Availability • Ease of production and dissemination • Potential for high morbidity and mortality causing major health impacts | Emerging Infectious Diseases | Nipah Virus Hantaviruses Tick-Borne Hemorrhagic Fever Viruses Tick-Borne Encephalitis Viruses Yellow Fever Multidrug-Resistant Tuberculosis |
Centers for Disease Control and Prevention (CDC) Biological Agent Categories (
Category B agents are the second-highest priority agents and typically include agents that are responsible for moderate morbidity and low mortality rates, and are moderately dispersible (
Category considerations of biological agents vary between the Centers of Disease Control and Prevention (CDC) and the US National Institute of Allergy and Infectious Diseases (NIAID) based upon circumstance of the infectious agent. The CDC assesses bioagent risks in support of US public health systems and primary healthcare providers and how, based upon the categorization, they should respond to biological agents and pathogens including those that seldom occur in the US (
HCPS-Causing New-World Hantaviruses
The hantavirus genus forms part of the Bunyavirus family and is composed of well-defined serotypes that are each associated with a specific primary rodent reservoir (Spiropoulou et al., 1994;
FIGURE 2

Hantavirus structure. Hantaviruses are enveloped with a lipid bilayer containing Glycoprotein spikes assemblies comprised of Gn and Gc Glycoproteins. Contained within the envelope are the equimolar amounts of N Protein packaged S (small), M (medium), and L (large) segments vRNA, which are associated with an RdRp (
The L Segment’s RdRp acts as the RNA transcriptase and replicase, transcribing mRNA and replicating the genomic RNA using the positive-sense RNA as an intermediate (Kukkonen et al., 2005) (Figure 3). Hantaviral RNA segments are each associated with the RdRp and are packaged within a ribonucleoprotein complex formed by the N Protein (
FIGURE 3

HCPS-causing hantavirus life cycle. Pathogenic HCPS-causing hantaviruses such as SNV or ANDV will first bind to β3-Integrin receptors on endothelial cells which will mediate endocytosis. The formation of an early endosome helps traffic the virion to the Golgi Complex. Following a pH-mediated membrane fusion, the now late endosome disassembles and releases the ribonucleoproteins (RNPs) near the Endoplasmic Reticulum-Golgi Intermediate Compartment (ERGIC). The RNPs disassemble and the RdRp carries out transcription and replication in the cytoplasm, cleaving cellular mRNA to form capped primers to initiate viral mRNA transcription. Transcribed S, M, and L Segment mRNA is translated into N Protein, GPC (and then into co-translated Gn and Gc Glycoproteins), and RdRp respectively. Negative-sense vRNA serves as the template for the transcription of mRNA. RdRp undergoes a transition from transcription to the replication of negative-sense vRNA which is considered to be mediated by the increase in free N Protein concentration (
Pathogenic hantaviruses retain glycoproteins that target and interact with the β3 chain of Integrins that is especially abundant as a surface receptor on endothelial cells, dendritic cells (DC), and platelets where they are critical in maintaining capillary integrity (
The N Protein’s role is multifaceted, but is primarily involved in the encapsidation of the vRNA and protects it from host cellular nucleases by binding selectively to Hantaviral panhandle structures (Mir and Panganiban, 2005;Mir et al., 2010). Each SNV segment possesses conserved terminal sequences at the 5′ and 3′ NTRs that are capable of complementarily base-pairing to form panhandle structures (
SNV and ANDV are the two major causative agents of HCPS, with ANDV occurring in South America which is spread by the Sigmondontinae subfamily and mainly by Oligoryzomys longicaudatus or the long-tailed pygmy rice rat reservoir (
The reservoirs themselves can spread the virus horizontally, being nearly asymptomatic but chronically infected (
Hantaviruses generally enter cells utilizing a clathrin-dependent pathway which follows the formation of an early endosome and subsequent low-pH initiating dissolution of the late endosome for infectious entry (
Hantavirus infections activates the innate immune system with downstream effects that induces disease. The innate immune system recognizes pathogens through their interaction with Pattern Recognition Receptors (PRRs) which are expressed by many cell types, including endothelial and epithelial cells. Viruses present Pathogen-Associated Molecular Patterns (PAMPs) which are recognized by PRRs which activate signaling cascades and transcription factors that modulate the expression of type I Interferons and Interferon-Stimulating Genes (ISGs) involved in antiviral functions. Toll-like Receptors (TLRs) and Retinoic acid-Inducible Gene-I (RIG-I), including the RIG-I-like receptor Melanoma Associated Gene 5 (MDA5), are PRRs that are involved in the recognition of pathogenic RNA viruses by binding to vRNA (
New World Hantaviral proteins antagonize virus recognition by suppressing the JAK/STAT signaling pathways with ANDV utilizing its N Protein and the GPC to disrupt antiviral activity while SNV employs its GPC alone (Levine et al., 2010). The N Protein of hantaviruses has been reported to inhibit IFN activity and NF-κB activation, with ANDV N Protein inhibiting signaling responses instigated by RIG-I and MDA5 and upstream IRF3 phosphorylation (Taylor et al., 2009;
Symptoms
Patients suffering from HCPS generally present fever, headache, muscle aches, and chills as well as leukocytosis and thrombocytopenia, which rapidly progresses to more severe respiratory diseases (Schmaljohn and Hjelle, 1997). After 4–10 days, individuals infected with HCPS-causing hantaviruses developed influenza-like illnesses followed by rapidly progressing pulmonary edema caused by pulmonary capillary leak syndrome, resulting in respiratory dysfunction and shock (Zaki et al., 1995; Schmaljohn, 2009). HCPS is particularly important because unlike other respiratory diseases, it occurs in young, healthy adults (
Vaccines and Therapeutics
There are no US FDA-approved vaccines available for hantavirus infections, however, there are a variety of live-attenuated vaccines (Hantavax), DNA vaccines, subunit vaccines, and virus-like particle (VLP) vaccines that all demonstrate varying degrees of effectiveness (Schmaljohn et al., 1992;
There are currently no US FDA-approved post-exposure therapeutics against Hantaviral infections, however, there are treatment strategies present to manage HFRS and HCPS (Liu et al., 2019). Virus-targeting antivirals including antiviral drugs, antibodies, or novel-small molecules are designed to block hantavirus entry or to reduce viral replication. Ribavirin is an effective anti-Hantaviral drug that affects the biological function of RdRp and has had some success in treating HFRS cases including protecting Syrian hamsters in lethal HCPS models (Safronetz et al., 2011; Warner et al., 2019b). Ribavirin was effective at preventing lethal HCPS disease by having an inhibitory effect on ANDV replication (Safronetz et al., 2011). Ribavirin also inhibits SNV in vitro while the pre-treatment of deer mice followed by daily therapy of Ribavirin reduced SNV infection and viral RNA synthesis (Medina et al., 2007). However, Ribavirin has some limitations as at high doses it is toxic to humans and animals and causes anemia (McKeeJr., Huggins et al., 1988;
Hantaviruses can be inactivated by heat (sustained 30 min at 60°C), detergents, UV radiation, organic solvents, and hypochlorite solutions (
Biowarfare Potential of HCPS-Causing Hantaviruses
Hantaviruses have generally remained in the Category C position from the CDC and biodefense categorizations which is different from the laboratory biosafety criteria summarized in Table 2. Hantaviruses are considered a biosafety level 3 bioagent with regards to NIH and across the European Union (EU), with the exception of HCPS-causing hantaviruses in the EU being considered a level 2 because their criteria differ with regards to an agent that causes human disease and might be a hazard to workers, but is unlikely to spread to the community, and there is usually effective prophylactic treatment available (Tian and Zheng, 2014). For comparison, the NIH treats Ebola virus as a level 4; Bacillus anthracis as a level 2; SARS-associated coronavirus (SARS-CoV) as a level 3; and Human Immunodeficiency Virus (HIV) as a level 3; regardless of the biosafety levels, both Ebola Virus and Anthrax are considered very high biothreats with hantavirus being a high threat in the EU (Tian and Zheng, 2014). BSL 3 laboratory requirements are intensive, especially for highly pathogenic diseases that can cause harm to materials and personnel. Incidentally, for a research or industrial laboratory to study hantaviruses they require: direct physical protection from the virus in the form of PPE including gloves, masks, gowns, respiratory protection, and positive pressure ventilation suits; Biosafety Cabinets (BSC) as primary containments to isolate the pathogen and the user; secondary containments to mitigate or prevent the pathogen’s presence outside the BSC and its exit outside BSL 3 containment; and physical barriers in the form of walls, fences, or exclusion zones to prevent outside contamination (Pastorino et al., 2017). The initial infrastructural costs and maintenance of BSL 3 containment protocols would be prohibitively expensive and complex for uninitiated bioterrorist organizations making its development by smaller, resource poor organizations unfeasible.
TABLE 2
| Requirements | |
| 1 | Agents that are not associated with disease in healthy adult humans. |
| 2 | Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. |
| 3 | Agents that are associated with serious or lethal human disease for which preventive or therapeutic interventions may be available (can cause high individual risk but low community risk). |
| 4 | Agents that are likely to cause serious or lethal human disease for which preventive or therapeutic interventions are not usually available (can cause high individual risk and high community risk). |
Biosafety categorization based upon the National Institute of Health (NIH) Criteria (Tian and Zheng, 2014).
Hantaviruses are cited as being possible bioweapons that can be used against humans. When focused on specific serotypes of hantavirus, like SNV and ANDV, it becomes apparent that with their high mortality rate and rapid disease course with serious cardiopulmonary symptoms New-World Hantaviruses as opposed to HFRS-causing Old-World Hantaviruses are the more severe threat (
TABLE 3
| Requirements | Risk | Condition | |
| 1 | Availability in the Environment | Medium | Wide range of Rodent Host Reservoirs in North and south America |
| 2 | Ease of Design and Production | Medium | Possible Attenuation through Passaging Few Nonhuman Primate Lethal Disease Models Difficulty in Isolation and Purification of Virions New Technology improving yields and Virulence of Passaged Virions |
| 3 | Stability after Production and Persistence in the Environment | Medium | Long Durability and Persistence in Contained and Isolated Environments Sensitivity to Light and Heat |
| 4 | Effective Transmission Pattern and Routes of Entry | Medium | Inhalation of both ANDV and SNV Person-to-Person Transmission of ANDV |
| 5 | Effective Delivery Systems and Mode of Transportation | Medium | Effective Deployment Indoors Rodent Delivery is Onerous and Resource Intensive |
| 6 | Susceptible Target Population | High | Novel Emerging Infectious Disease with no known natural immunity within Human Populations |
| 7 | Absence of Specific and Effective Treatment including countermeasures that have the Ability of a Vaccine to Protect Certain Groups | High | No US FDA approved Antivirals or vaccines Some Antivirals and Vaccines for Old-World Hantaviruses with varying Degrees of Effectiveness |
| 8 | The Ability to Incapacitate or Kill Target Host | Medium | High Mortality Rate Low Morbidity Rate |
| 9 | Appropriate Particle Size for Aerosolization and Airborne Transmission | Medium | Can be Aerosolized Airborne Efficiency within Closed Environments |
| 10 | The Ability to be Disseminated in Food or Water Supplies | High | Can Contaminate Food and Water as well as commercial products |
| 11 | Logistic Requirements to Manufacture and Disperse Bioagents which include Infrastructural and Financial Support, Expertise, and Organizational Capabilities | Low | Intensive Laboratory Equipment and High Expertise Requirements High Costs Deployment of Infected Rodents Reservoirs is Demanding |
Summary of ideal Biological Warfare Requirements adapted and modified from Meyer and Morse (2008) and
Table also includes the capabilities required by conventional or unconventional militaries to conduct and deliver a bioagent attack. Note that the ranking is unimportant. We also describe the risks associated with bioweapons requirements as they pertain to the feasibility of developing and deploying New-World Hantaviruses. Risk is graduated with regard to Low, Medium, and High.
HCPS-Causing Reservoirs Are Available and Are Affected by Environmental Factors
The presence of SNV-infected deer mice across the American Midwest is fairly high as seroprevalence of SNV antibodies were discovered in 38% of captured rodents in Indiana, with up to 25% of seroprevalence in the western US and 7% in the eastern US (
Climate change will also have impacts to the acquisition and maintenance of Hantaviral reservoirs. Rodent population dynamics are particularly affected by a combination of unusually high rainfall followed by drought which is evidenced by the 1993 US Four Corners outbreak which was preceded by a dramatic increase in rainfall following the 1992–1993 El Niño warming phase (
Bioterrorist cells have the potential to take advantage of high rodent population densities. Having higher populations of asymptomatic but chronically infected rodent specimens can be utilized in either a one-target distribution model, or as a means to generate a critical concentration of passaged virions to achieve a weaponizable aerosol. Both methods would require a large-scale capture and maintenance of rodents, with the latter being more onerous in the process of passaging and isolating the hantavirus. However, the role of climate change provides access for bioterrorist groups to acquire the virus through freely available infected rodents because of their increased populations. This can change depending on the effects of human activity which is being accelerated by agricultural expansion, deforestation, land reclamation, irrigation projects, and infrastructural developments (
Difficulty in Cell Culturation Reduces Ease of Production
Hantaviruses have historically been very difficult to isolate and grow in both cell culture and animal models, which have limited their ability to be previously concentrated and weaponized (
The previous reporting of hantavirus being difficult to isolate have also been attributed to the low concentrations of infectious virion particles extracted from the clinical or wild-caught infected rodents, with virion replication peaking at the time of death for the HCPS-infected human patients (
Although tough and resource demanding, concentrating hantaviruses is not impossible and may become more efficient with newer technologies and techniques as Warner et al. (2019a) demonstrated. A way to increase viral stocks is to avoid using the standard intramuscular model of infection and instead use the intraperitoneal infection of deer mice which was demonstrated to produce SNV stocks with high viral RNA copy number (Warner et al., 2019a). New immunotherapies methods leading toward lethal disease models are also helping to increase the viral load as the infection of immunocompetent Syrian hamsters with cell-cultured SNV resulted in lower levels of viral dissemination compared to immunocompromised hamsters (
Additionally, given the rise in genetic engineering tools and techniques such as TALEN and CRISPR/Cas9, the ability to synthetically engineer more pathogenic bioagents is available (
Susceptible Targets
Conventional Warfare Settings
Militaries and hantaviruses have a deep history which is largely tied with the operation of war and the requirements that are needed to support it (
Puumala virus causes a milder form of HFRS called Nephropathia Epidemica (NE) and is spread by the bank vole in Europe (Vapalahti et al., 2003). It is suspected that hantaviruses, specifically PUUV, spread across Europe during WWI in the form of Trench Nephritis which can be attributed to the congestion of soldiers and rodents in tight places, including trench lines that destroyed farmland and undermined infrastructure (
Consequently, the military is a natural target for hantavirus as a result of their activities occurring in largescale field exercises or in land-based combat which can disrupt natural habitats and cause exposure to hantaviruses by dispersing HCPS-causing rodents as was the case for HFRS-causing Apodemus agrarius or the striped field mouse (
Within the range of the military, it would be appropriate to develop strategies to delay or inundate military forces by exposure to hantavirus through natural infection models. This would observe HCPS-causing hantaviruses to be deployed as area denial weapons which are employed to slow the advance or endanger target militaries. Area denial weapons tend to restrict the momentum of target forces, usually forcing them into positions of vulnerability which may include adopting additional precautions to manage and mitigate the effects of the bioweapon itself. Employing New-World Hantaviruses in this respect, whether it be the physical dispersal of HCPS-infected rodents to undermine the entrenched living conditions of soldiers, or the deployment of aerosolized virion particles would significantly affect the morale, strength, and movement of the target army. A strategy of area denial would be to harbor HCPS-causing rodents in built-up areas to prevent the appropriation of urban infrastructure by an invading force. Abandoned facilities would be especially exceptional since SNV is found highly aerosolized in small, ≤1 μm particulate matter that is far-more easily disturbed to the breathing zone (1.5 m height) from walking rather than sweeping (Richardson et al., 2013). Soldiers seizing urban areas would be most vulnerable, especially during the spring and summer months where reservoir breeding and particulate aerosolization increases (Waltee et al., 2009). SNV may also persist in excreta for longer since sunlight and UV radiation are blocked from actively degrading the virions due to the protection vacant buildings provide (
Unconventional Warfare Settings and Civilian Targets
Targets to a country’s civilian populace or economic and industrial sectors are important alternatives for bioterrorist organizations or low-parity nations that cannot compete with modern industrial militaries. As illustrated by the 2019 SARS-CoV-2 pandemic, infectious diseases have the effect of compromising the entire socio-economic systems of countries and will be a practical target for most bioterrorist organizations. A bioweapons’ attack will likely force the civilian populace to seek shelter or undergo rigorous quarantine measures which will affect the consumption of products from primary and secondary sectors of industry. The 2019 SARS-CoV-2 pandemic’s quarantining especially reduced demand for oil and petroleum products, manufacturing, and agriculture worldwide as isolated civilians were no longer able to consume and grow the economy at previous rates resulting in a decline in overall national GDP (Nicola et al., 2020). Furthermore, impediments to the social fabric caused by the pandemic resulted in an overall abated pattern of life that observed closures of schools, increased hospitalization and pressures on the medical systems, as well as an increase in government debt and expenditure to maintain the stability of their financial sectors (Nicola et al., 2020). HCPS-causing Hantaviral bioweapons could be deployed in this way to afflict damage to a nation’s industrial output or to invoke panic amongst a civilian populace which would affect a country’s ability to fight conflicts abroad or domestically.
Farmers are naturally affected by the presence of hantaviruses due to their outdoor activities and cultivation of farmland which overlap rodent reservoir habitats (Vapalahti et al., 1999). A possible biothreat scenario involving hantavirus would likely target agriculture centers by increasing the incidence of contact with HCPS-causing rodents preventing farmers from working or by forcing them to require additional and costly protective equipment which would create delays in production. This includes traditional farmers utilizing lumber as a fuel source as firewood handling could result in the close contamination from Hantaviral infected aerosols or dust (Van Loock et al., 1999). The risk from storage or lumber shelters will especially affect those in the lumber and forestry industries and can thus be a target for a slow delivery in addition to an either targeted or widescale dispersal of hantavirus bioweapon which would delay or harass industrial production.
Hantaviruses, because of their global nature, have the capacity to affect infrastructure especially shipping and trade. Given a major outbreak, major ports contaminated with aerosolized hantaviruses have the capacity to create delays in trade which will endanger the economy of a target country. HFRS-causing SEOV is found worldwide because of its ubiquitous rodent reservoir the brown rat (Rattus norvegicus) whose close relationship with humans and subsequent dissemination through global trade, human migrations, and settlement has enabled its transit and viability (Lin et al., 2012). The presence of the brown rat in most major urban centers and in key transport industries such as maritime and land shipping can create a vulnerability to trade if targeted by bioterrorist organizations. Having a simple rodent infestation can threaten food stores and given hantaviruses general durability in moderate temperatures and low-UV light environments such as storage containers will allow aerosolized hantaviruses to survive up to 2-weeks and create hazards for government or civilian responders. Selective pressures and challenging environments like highlands, deserts, and cities will likely prevent dispersal of natural reservoirs of hantavirus such as deer mice. However, in North America, similar species to deer mice such as Peromyscus leucopus or the white-footed mouse have occupied effective niches in cities on the east coast of Canada and the United States and have taken advantage of urban environment’s lack of predators and natural competitors, its warmer climate for mating, and its abundance of small forest fragments for habitation (Munshi-South and Richardson, 2017). Attempting to build a natural reservoir in the city would take generations of rodent colonies and would itself be unviable given time, resources, and current rodent controls and proofing.
Hantaviruses also pose a risk to food consumption as well if improperly stored (Risteska-Nejashmikj et al., 2019; Wang et al., 2020). Hantaviruses, with PUUV and ANDV being studied, are not easily digested by stomach acids and can survive long enough to be passed into the gastrointestinal tract. Despite the requirements for intragastric route infection being the least effective, the oral route of infection is plausible for PUUV (Witkowski et al., 2017). Contaminating food and water supplies with biological weapons generally produces fewer casualties compared to an airborne release, but may be a secondary consequence resulting from a primary release (White, 2002). This would be the effect of having a warehouse contaminated with Hantaviral aerosols which will contaminate food stocks contained in tin cans or boxed containers. The consequence is two-fold. The first involves the vast stores of merchandise and material needing to undergo rigorous decontamination or disposal to prevent subsequent human contact and illness which will affect economic output. The second, if successful, will cause an indirect aerosol route of transmission to humans which could be widespread due to the nature of modern supply chains and distribution.
Hantaviruses are only currently pathogenic to humans as their rodent reservoirs remain chronically infected and asymptomatic of the disease, however, they continue to be highly viremic as the natural host produces antibodies including neutralizing antibodies (Netski et al., 1999;
One of the limitations of hantaviruses is that they spread by specific rodent host species with most being spread by one or a few closely related rodents which reflect the co-evolutionary relationships hantaviruses generally have with their reservoirs (
ANDV and SNV are genetically distinct hantaviruses that circulate in different regions and different rodent reservoirs. Despite ANDV not being maintained in deer mice, it can infect the SNV rodent reservoir allowing for new serotypes to occur (
Naturally occurring SNV reassortments are rather limited though and generally occur within local deer mouse populations just because of the local ecology supporting so few rodent species who rarely encounter each other and allow natural reassortment to occur. This is also undermined by the increasing genetic distance between rodent species that make reassortments less frequent (
Transmission
Compared to other hantaviruses like PUUV which readily transmits between bank voles and persists effectively within the environment, SNV retains some limitations to its transmission both horizontally between rodents and vertically to humans (
While all hantaviruses are spread to humans via the inhalation of contaminated dust and aerosols dispersed from rodent feces, urine, saliva, and fur, the viability of its spread is limited to peridomestic risk areas such as barns, cabins, or warehouses (
Unlike SNV and other hantaviruses, ANDV has a distinguishable route of transmission because of its ability to spread person-to-person exemplified by several small cluster outbreaks in Southern Chile and Argentina (Toro et al., 1998; Martinez et al., 2005). For person-to-person transmission to occur, close contact is required which increases the risk to people living in the same household as well as sexual partners. The presence of ANDV in the alveolar epithelium and salivary glands of Sigmondontine rodents reinforces intraspecies transmission from saliva and biting (Padula et al., 2004). ANDV infected patients have shown the virus to be present in pneumocytes and pulmonary macrophages, with ultrastructural and immunocytochemical studies revealing viral replication occurring in the alveolar epithelial cells with virus-like particles being released into the alveolar lumen (Pizarro et al., 2019). ANDV is likely secreted into human saliva and transmitted through close, intimate encounters or by exposure to respiratory droplets released through coughing or sneezing. There has also been reports of person-to-person transmission of ANDV from breast milk to new-borns, compounded by the new-borns’ inadequate immune system and the presence of vRNA in the breast milk (
Dispersal and Delivery
Since hantaviruses are transmitted to humans from rodents, a rudimentary but deliberate release of infected rodents into a target location would be a relatively easy way to threaten public health (Lõhmus et al., 2013). The impact would be low, but a strike against a country’s key infrastructure like trade ports, warehouses, hospitals, governments centers, or public gatherings with infected rodents would create delays to productivity and the economy. Modern, industrialized countries in the west would not undergo famine or experience food insecurity as a result of a biological attack to the agriculture sector because of its robustness in diversity, high-production and heightened regulation (Wheelis et al., 2009). However, disruptions caused by the presence of suspected or confirmed biological agents has the potential to inflict market speculation and contraction through bans on international food exports resulting in lost revenue, job losses, and the destruction of capital including livestock or contaminated merchandise. This is indicated by the pig and cow culling during the Foot and Mouth Disease and the Bovine Spongiform Encephalopathy outbreaks in the United Kingdom, United States, and the Republic of China in 1997 and the early 2000s (
Rodent dispersal is discreet and innocuous, and can go unnoticed compared to bioweapons deployed by artillery, missiles, or by aerial deployment by aerosols. One limitation of Hantaviral deployment by artillery or missile is due to its 60°C heat sensitivity as any incendiary or kinetic deployment system would inactivate and degrade Hantaviral virions (White, 2002). The preferable deployment mechanism would be an aerosolization or powdered pathway which is undetectable and can achieve rapid dispersal over a wide area (White, 2002). Hantavirus delivery could benefit from similar dispersal methods employed to transport Anthrax or Ricin toxins such as letters and mailed packages due to their persistence in UV-free environments (
There does exist substantial methods of rodent and pest controls that target deer mice through bait and trappings, structural proofing and rodenticides which have proven both economical and effective in preventing rodent entry to structures including underdeveloped residences (
ANDV virus would be the preferred model for dispersal if conducting a specific one-target attack with collateral to personnel within an immediate vicinity. This is because ANDV can occur within household person-to-person contact and can cause up to 25–35% mortality rates (Krüger et al., 2011). An attack on a single target with the intent of causing panic and successive but limited infections within a household would be an unideal although possible diversionary method for assassination. Household contacts of ANDV are at risk of developing HCPS infections within 4 weeks with ANDV vRNA being routinely detected in blood cells for up to 2 weeks before symptoms or anti-hantavirus antibodies arise (
Conclusion
With the limitations present, HCPS-causing hantaviruses are generally restricted to the Category C definition largely because their spread and ability to be concentrated in the laboratory faces difficult barriers. The feasibility of developing HCPS-causing bioweapons comes from the few strengths hantaviruses possess which includes its high mortality rate. Hantaviruses can also be easily dispersed through aerosols if limited to indoor facilities or warehouses with no insolation and can effectively target personnel – especially the military – operating in close proximity to rodent reservoir habitats. HCPS-causing hantaviruses also benefit from being difficult to treat since no Old-World Hantavirus antivirals or vaccines have effective specificity against them. However, the morbidity rate of New-World Hantaviruses is very low, with ANDV being a potential but somewhat viable agent because of its person-to-person transmission pathway which would likely infect more people. Additionally, the ability to manufacture and produce ANDV or SNV into a lethal form that can be dispersed poses a problem to its weaponization due to the presence of attenuating mutations and absence of a strong disease model for non-human primates. Although widespread, the ability for HCPS-causing hantavirus reservoirs to adopt new urban environments is limited but may be improved by the effects of climate change and the increase in human industrial activity. As technologies improve and barriers to passaging and replicating hantavirus virions in culture become easier and more viable, the ability to mass-produce pathogenic HCPS-causing hantaviruses like SNV or ANDV may upgrade hantaviruses from a Category C to A definition.
Nevertheless, despite being a Category C pathogen, the threat of hantaviruses infections generally and the potential for it to be weaponized should not be ignored. Hantaviruses are emerging pathogens that require the attention of government and medical health research as globally they still occur frequently in developing countries with poor infrastructure or in rural, agrarian environments that have close contact with Hantaviral rodent-reservoirs. Hantavirus and HCPS continue to be a serious pathogen and disease to be considered carefully due to the environmental-associated risks of frequent rodent-human contact that expose military personnel, farmers and agriculture workers, and warehouse and shipping staff to the virus. The paucity of reporting in developing countries and the neglect that hantaviruses face allows it to slip under the radar and can be exploited by organizations that could potentially field extensive laboratory equipment and rodent reservoirs toward the development of hantavirus-based biological weapons. Infectious diseases generally can be mitigated with better reporting and surveillance, especially by monitoring the incidence of disease through extensive international health and medical networks. This can be accomplished by governments and academic agencies resolving to be proactive in testing, freely sharing clinical and experimental details, and maintaining intergovernmental transparency with regard to pandemics or the occurrence of bioweapon threats (
Globally, the ability to employ biological agents is prohibited by the Biological and Toxin Weapon Convention (BTWC) ratified by the United Nations and 170 of their member states which has limited international biological warfare. However, because of their lack of inspection mechanisms, rogue states and terrorist organizations could circumvent the BTWC treaty and employ biological weapons against target nations (
As a consideration, significant international and national cooperation must occur to safeguard global trade, public health, and international security from bioterrorism. Mitigation strategies against bioagent attacks can only be effective given the invested interests of governments and research scientists in protecting the health of their peoples. Incidentally, research into medical health science must be focused on building toward detection, identification, mitigation and management equipment and techniques with the concentration of resources from cooperating governments to fund developments in counter-terrorism and medical therapeutics. This would require an intergovernmental exchange of communication between research scientists, policy-makers, and the public to broaden transparency toward international security and scientific research (Zhao et al., 2020). Through cooperation, predictions of future attacks or employment of bioagents can be ascertained, preventing socio-economic collapses that could occur from industry-paralyzing infectious diseases.
Statements
Author contributions
MD’S and TP: conceptualization, formal analysis, writing, and visualization. TP: supervision and funding acquisition. Both authors read and agreed to the published version of the manuscript.
Funding
We thank Canada Research Chair program.
Acknowledgments
TP acknowledges Canada Research Chair Program. Hantavirus Structure and Lifecycle Figures were prepared by Tyler Lieberthal (darkbloom) as a commercial service.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AlonsoD. O.IglesiasA.CoelhoR.PerioloN.BrunoA.CordobaM. T.et al (2019). Epidemiological description, case-fatality rate, and trends of Hantavirus Pulmonary Syndrome: 9 years of surveillance in Argentina.J. Med. Virol.911173–1181. 10.1002/jmv.25446
2
AlonsoD. O.Perez-SautuU.BellomoC. M.PrietoK.IglesiasA.CoelhoR.et al (2020). Person-to-person transmission of andes virus in hantavirus pulmonary syndrome, Argentina, 2014.Emerg. Infect. Dis.26756–759. 10.3201/eid2604.190799
3
AlthausC. L. (2014). Estimating the Reproduction Number of Ebola Virus (EBOV) During the 2014 Outbreak in West Africa.PLoS Curr.6:ecurrents.outbreaks.91afb5e0f279e7f29e7056095255b288. 10.1371/currents.outbreaks.91afb5e0f279e7f29e7056095255b288
4
AmrounA.PrietS.de LamballerieX.QueratG. (2017). Bunyaviridae RdRps: structure, motifs, and RNA synthesis machinery.Crit. Rev. Microbiol.43753–778. 10.1080/1040841x.2017.1307805
5
ArthurR. R.LeducJ. W.HughesJ. M. (2006). Surveillance for emerging infectious diseases and bioterrorism threats.Trop. Infect. Dis.2006195–200.
6
AstorgaF.EscobarL. E.Poo-MunozD.Escobar-DoderoJ.Rojas-HucksS.Alvarado-RybakM.et al (2018). Distributional ecology of Andes hantavirus: a macroecological approach.Int. J. Health Geogr.17:22.
7
Avsic-ZupancT.SaksidaA.KorvaM. (2019). Hantavirus infections.Clin. Microbiol. Infect.21se6–e16.
8
BagamianK. H.TownerJ. S.KuenziA. J.DouglassR. J.RollinP. E.WallerL. A.et al (2012). Transmission ecology of Sin Nombre hantavirus in naturally infected North American deermouse populations in outdoor enclosures.PLoS One7:e47731. 10.1371/journal.pone.0047731
9
BaldwinR. A.QuinnN.DavisD. H.EngemanR. M. (2014). Effectiveness of rodenticides for managing invasive roof rats and native deer mice in orchards.Environ. Sci. Pollut. Res. Int.215795–5802. 10.1007/s11356-014-2525-4
10
BellomoC.AlonsoD.CoelhoR.IglesiasA.PerioloN.MartínezV. P. (2020). A newborn infected by Andes virus suggests novel routes of hantavirus transmission: a case report.Clin. Microbiol. Infect.26130–131. 10.1016/j.cmi.2019.09.012
11
Beltran-OrtizC. E.Starck-MendezM. F.FernandezY.FarnosO.GonzalezE. E.RivasC. I.et al (2017). Expression and purification of the surface proteins from Andes virus.Protein Expr. Purif.13963–70. 10.1016/j.pep.2015.09.013
12
BenjaminR.BergesB. K.Solis-LealA.IgbinedionO.StrongC. L.SchillerM. R. (2016). TALEN gene editing takes aim on HIV.Hum. Genet.1351059–1070. 10.1007/s00439-016-1678-2
13
BerlJ. L.KuenziA. J.FlahertyE. A.SwihartR. K. (2018). Interspecific comparison of hantavirus prevalence in peromyscus populations from a fragmented agro-ecosystem in Indiana, USA.J. Wildl. Dis.54147–150.
14
BhallaD. K.WarheitD. B. (2004). Biological agents with potential for misuse: a historical perspective and defensive measures.Toxicol. Appl. Pharmacol.19971–84. 10.1016/j.taap.2004.03.009
15
BorgesA. A.CamposG. M.MoreliM. L.SouzaR. L.AquinoV. H.SaggioroF. P.et al (2006). Hantavirus cardiopulmonary syndrome: immune response and pathogenesis.Microbes Infect.82324–2330. 10.1016/j.micinf.2006.04.019
16
BrocatoR. L.HammerbeckC. D.BellT. M.WellsJ. B.QueenL. A.HooperJ. W. (2014). A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.J. Virol.88811–819. 10.1128/jvi.02906-13
17
BrocatoR. L.HooperJ. W. (2019). Progress on the prevention and treatment of Hantavirus disease.Viruses11:610. 10.3390/v11070610
18
BrownB. A.PanganibanA. T. (2010). Identification of a region of hantavirus nucleocapsid protein required for RNA chaperone activity.RNA Biol.7830–837. 10.4161/rna.7.6.13862
19
BugertJ. J.WelzelT. M.ZeierM.DaraiG. (1999). Hantavirus infection–haemorrhagic fever in the Balkans–potential nephrological hazards in the Kosovo war.Nephrol. Dial. Transplant.141843–1844. 10.1093/ndt/14.8.1843
20
CDC (2018). Bioterrorism Agents/Diseases. Available online at: https://emergency.cdc.gov/agent/agentlist-category.asp(accessed March 30, 2020).
21
ChapmanL. E.MertzG. J.PetersC. J.JolsonH. M.KhanA. S.KsiazekT. G.et al (1999). Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group.Antivir. Ther.4211–219.
22
ChengE.WangZ.MirM. A. (2014). Interaction between hantavirus nucleocapsid protein (N) and RNA-dependent RNA polymerase (RdRp) mutants reveals the requirement of an N-RdRp interaction for viral RNA synthesis.J. Virol.888706–8712. 10.1128/jvi.00405-14
23
ChiangC. F.FlintM.LinJ. S.SpiropoulouC. F. (2016). Endocytic pathways used by Andes virus to enter primary human lung endothelial cells.PLoS One11:e0164768. 10.1371/journal.pone.0164768
24
ChizhikovV. E.SpiropoulouC. F.MorzunovS. P.MonroeM. C.PetersC. J.NicholS. T. (1995). Complete genetic characterization and analysis of isolation of Sin Nombre virus.J. Virol.698132–8136. 10.1128/jvi.69.12.8132-8136.1995
25
ChoH. W.HowardC. R. (1999). Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax).Vaccine172569–2575. 10.1016/s0264-410x(99)00057-2
26
ChoiY.AhnC. J.SeongK. M.JungM. Y.AhnB. Y. (2003). Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells.Vaccine211867–1873. 10.1016/s0264-410x(03)00005-7
27
ChristianM. D. (2013). Biowarfare and Bioterrorism.Crit. Care Clin.29717–756. 10.1016/j.ccc.2013.03.015
28
CimicaV.DalrympleN. A.RothE.NasonovA.MackowE. R. (2014). An innate immunity-regulating virulence determinant is uniquely encoded by the Andes virus nucleocapsid protein.mBio5:e01088-13.
29
ClementJ.UnderwoodP.WardD.PilaskiJ.LeDucJ. (1996). Hantavirus outbreak during military manoeuvres in Germany.Lancet347336. 10.1016/s0140-6736(96)90519-x
30
ClementJ. P. (2003). Hantavirus.Antiviral Res.57121–127.
31
Connolly-AndersenA. M.SundbergE.AhlmC.HultdinJ.BaudinM.LarssonJ.et al (2015). Increased Thrombopoiesis and Platelet Activation in Hantavirus-Infected Patients.J. Infect. Dis.2121061–1069. 10.1093/infdis/jiv161
32
Connolly-AndersenA. M.ThunbergT.AhlmC. (2014). Endothelial activation and repair during hantavirus infection: association with disease outcome.Open Forum Infect. Dis.1:ofu027.
33
de St MauriceA.ErvinE.SchumacherM.YaglomH.VinHattonE.MelmanS.et al (2017). Exposure characteristics of hantavirus pulmonary syndrome patients, United States, 1993-2015.Emerg. Infect. Dis.23733–739. 10.3201/eid2305.161770
34
DoganayM.DemiraslanH. (2015). Human anthrax as a re-emerging disease.Recent Pat. Antiinfect. Drug Discov.1010–29. 10.2174/1574891x10666150408162354
35
DouglassR. J.SemmensW. J.Matlock-CooleyS. J.KuenziA. J. (2006). Deer mouse movements in peridomestic and sylvan settings in relation to Sin Nombre virus antibody prevalence.J. Wildl. Dis.42813–818. 10.7589/0090-3558-42.4.813
36
DrebotM. A.JonesS.GrollaA.SafronetzD.StrongJ. E.KobingerG.et al (2015). Hantavirus pulmonary syndrome in Canada: an overview of clinical features, diagnostics, epidemiology and prevention.Can. Commun. Dis. Rep.41124–131. 10.14745/ccdr.v41i06a02
37
DudleyJ. P.WoodfordM. H. (2002). Bioweapons, bioterrorism and biodiversity: potential impacts of biological weapons attacks on agricultural and biological diversity.Rev. Sci. Tech.21125–137. 10.20506/rst.21.1.1328
38
DuehrJ.McMahonM.WilliamsonB.AmanatF.DurbinA.HawmanD. W.et al (2020). Neutralizing monoclonal antibodies against the Gn and the Gc of the Andes virus glycoprotein spike complex protect from virus challenge in a preclinical hamster model.mBio11:e00028-20.
39
EckerleI.LenkM.UlrichR. G. (2014). More novel hantaviruses and diversifying reservoir hosts–time for development of reservoir-derived cell culture models?Viruses6951–967. 10.3390/v6030951
40
ElliottL. H.KsiazekT. G.RollinP. E.SpiropoulouC. F.MorzunovS.MonroeM.et al (1994). Isolation of the causative agent of hantavirus pulmonary syndrome.Am. J. Trop. Med. Hyg.51102–108.
41
EmenyJ. M.MorganM. J. (1979). Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production.J. Gen. Virol.43247–252. 10.1099/0022-1317-43-1-247
42
EngelthalerD. M.MosleyD. G.CheekJ. E.LevyC. E.KomatsuK. K.EttestadP.et al (1999). Climatic and environmental patterns associated with hantavirus pulmonary syndrome, Four Corners region, United States.Emerg. Infect. Dis.587–94. 10.3201/eid0501.990110
43
ErmonvalM.BaychelierF.TordoN. (2016). What do we know about how Hantaviruses interact with their different hosts?Viruses8:223. 10.3390/v8080223
44
Escalera-AntezanaJ. P.Torrez-FernandezR.Montalvan-PlataD.Montenegro-NarvaezC. M.Aviles-SarmientoJ. L.Alvarado-ArnezL. E. (2020). Orthohantavirus pulmonary syndrome in Santa Cruz and Tarija, Bolivia, 2018.Int. J. Infect. Dis.90145–150. 10.1016/j.ijid.2019.10.021
45
FerresM.VialP.MarcoC.YanezL.GodoyP.CastilloC.et al (2007). Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile.J. Infect. Dis.1951563–1571. 10.1086/516786
46
FigueiredoL. T.SouzaW. M.FerresM.EnriaD. A. (2014). Hantaviruses and cardiopulmonary syndrome in South America.Virus Res.18743–54. 10.1016/j.virusres.2014.01.015
47
FonsecaL. X.OliveiraS. V.DuarteE. C. (2018). Magnitude and distribution of deaths due to hantavirus in Brazil, 2007-2015.Epidemiol. Serv. Saude27:e2017221.
48
ForbesK. M.SironenT.PlyusninA. (2018). Hantavirus maintenance and transmission in reservoir host populations.Curr. Opin. Virol.281–6. 10.1016/j.coviro.2017.09.003
49
FulhorstC. F.MonroeM. C.SalasR. A.DunoG.UtreraA.KsiazekT. G. (1997). Isolation, characterization and geographic distribution of Caño Delgadito virus, a newly discovered South American hantavirus (family Bunyaviridae).Virus Res.51159–171.
50
GajdusekD. C. (1962). Virus hemorrhagic fevers. Special reference to hemorrhagic fever with renal syndrome (epidemic hemorrhagic fever).J. Pediatr.60841–857.
51
GalenoH.MoraJ.VillagraE.FernandezJ.HernandezJ.MertzG. J.et al (2002). First human isolate of Hantavirus (Andes virus) in the Americas.Emerg. Infect. Dis.8657–661. 10.3201/eid0807.010277
52
GarcinD.LezziM.DobbsM.ElliottR. M.SchmaljohnC.KangC. Y.et al (1995). The 5′ ends of Hantaan virus (Bunyaviridae) RNAs suggest a prime-and-realign mechanism for the initiation of RNA synthesis.J. Virol.695754–5762. 10.1128/jvi.69.9.5754-5762.1995
53
GavrilovskayaI. N.BrownE. J.GinsbergM. H.MackowE. R. (1999). Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins.J. Virol.733951–3959. 10.1128/jvi.73.5.3951-3959.1999
54
GavrilovskayaI. N.ShepleyM.ShawR.GinsbergM. H.MackowE. R. (1998). beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure.Proc. Natl. Acad. Sci. U.S.A.957074–7079. 10.1073/pnas.95.12.7074
55
GlassG. E.JohnsonJ. S.HodenbachG. A.DisalvoC. L.PetersC. J.ChildsJ. E.et al (1997). Experimental evaluation of rodent exclusion methods to reduce hantavirus transmission to humans in rural housing.Am. J. Trop. Med. Hyg.56359–364. 10.4269/ajtmh.1997.56.359
56
GodoyP.MarsacD.StefasE.FerrerP.TischlerN. D.PinoK.et al (2009). Andes virus antigens are shed in urine of patients with acute hantavirus cardiopulmonary syndrome.J. Virol.835046–5055. 10.1128/jvi.02409-08
57
GoeijenbierM.AronG.AnfasaF.LundkvistA.Verner-CarlssonJ.ReuskenC. B. (2015). Emerging Viruses in the Republic of Suriname: retrospective and prospective study into Chikungunya Circulation and Suspicion of Human Hantavirus Infections, 2008-2012 and 2014.Vector Borne Zoonotic Dis.15611–618. 10.1089/vbz.2015.1798
58
GoldsmithC. S.ElliottL. H.PetersC. J.ZakiS. R. (1995). Ultrastructural characteristics of Sin Nombre virus, causative agent of hantavirus pulmonary syndrome.Arch. Virol.1402107–2122. 10.1007/bf01323234
59
GublerD. J.ReiterP.EbiK. L.YapW.NasciR.PatzJ. A. (2001). Climate variability and change in the United States: potential impacts on vector- and rodent-borne diseases.Environ. Health Perspect.109(Suppl. 2), 223–233. 10.1289/ehp.109-1240669
60
GuterresA.de LemosE. R. S. (2018). Hantaviruses and a neglected environmental determinant.One Health527–33. 10.1016/j.onehlt.2017.12.002
61
HardestamJ.SimonM.HedlundK. O.VaheriA.KlingstromJ.LundkvistA. (2007). Ex vivo stability of the rodent-borne Hantaan virus in comparison to that of arthropod-borne members of the Bunyaviridae family.Appl. Environ. Microbiol.732547–2551. 10.1128/aem.02869-06
62
HartlineJ.MierekC.KnutsonT.KangC. (2013). Hantavirus infection in North America: a clinical review.Am. J. Emerg. Med.31978–982. 10.1016/j.ajem.2013.02.001
63
HendersonW. W.MonroeM. C.St JeorS. C.ThayerW. P.RoweJ. E.PetersC. J.et al (1995). Naturally occurring Sin Nombre virus genetic reassortants.Virology214602–610. 10.1006/viro.1995.0071
64
HepojokiJ.StrandinT.LankinenH.VaheriA. (2012). Hantavirus structure–molecular interactions behind the scene.J. Gen. Virol.93(Pt 8), 1631–1644. 10.1099/vir.0.042218-0
65
HigaM. M.PetersenJ.HooperJ.DomsR. W. (2012). Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies.Virology423134–142. 10.1016/j.virol.2011.08.012
66
HjelleB.JenisonS.MertzG.KosterF.FoucarK. (1994). Emergence of hantaviral disease in the southwestern United States.West. J. Med.161467–473.
67
HooperJ. W.LarsenT.CusterD. M.SchmaljohnC. S. (2001). A lethal disease model for hantavirus pulmonary syndrome.Virology2896–14. 10.1006/viro.2001.1133
68
HopkinsA. S.Whitetail-EagleJ.CorneliA. L.PersonB.EttestadP. J.DiMennaM.et al (2002). Experimental evaluation of rodent exclusion methods to reduce hantavirus transmission to residents in a Native American community in New Mexico.Vector Borne Zoonotic Dis.261–68. 10.1089/153036602321131850
69
HughesA. L.FriedmanR. (2000). Evolutionary diversification of protein-coding genes of hantaviruses.Mol. Biol. Evol.171558–1568. 10.1093/oxfordjournals.molbev.a026254
70
HusseinI. T.HaseebA.HaqueA.MirM. A. (2011). Recent advances in hantavirus molecular biology and disease.Adv. Appl. Microbiol.7435–75. 10.1016/b978-0-12-387022-3.00006-9
71
HutchinsonK. L.PetersC. J.NicholS. T. (1996). Sin Nombre virus mRNA synthesis.Virology224139–149. 10.1006/viro.1996.0515
72
IannettaM.Di CaroA.NicastriE.VairoF.MasanjaH.KobingerG.et al (2019). Viral Hemorrhagic Fevers Other than Ebola and Lassa.Infect. Dis. Clin. North Am.33977–1002. 10.1016/j.idc.2019.08.003
73
JansenH. J.BreeveldF. J.StijnisC.GrobuschM. P. (2014). Biological warfare, bioterrorism, and biocrime.Clin. Microbiol. Infect.20488–496. 10.1111/1469-0691.12699
74
JiangH.ZhengX.WangL.DuH.WangP.BaiX. (2017). Hantavirus infection: a global zoonotic challenge.Virol. Sin.3232–43. 10.1007/s12250-016-3899-x
75
JinM.ParkJ.LeeS.ParkB.ShinJ.SongK. J.et al (2002). Hantaan virus enters cells by clathrin-dependent receptor-mediated endocytosis.Virology29460–69. 10.1006/viro.2001.1303
76
JohnsonK. M. (2001). Hantaviruses: history and overview.Curr. Top. Microbiol. Immunol.2561–14. 10.1007/978-3-642-56753-7_1
77
JonssonC. B.FigueiredoL. T.VapalahtiO. (2010). A global perspective on hantavirus ecology, epidemiology, and disease.Clin. Microbiol. Rev.23412–441. 10.1128/cmr.00062-09
78
JonssonC. B.HooperJ.MertzG. (2008). Treatment of hantavirus pulmonary syndrome.Antiviral Res.78162–169.
79
JonssonC. B.SchmaljohnC. S. (2001). Replication of hantaviruses.Curr. Top. Microbiol. Immunol.25615–32. 10.1007/978-3-642-56753-7_2
80
JoynerC. P.MyrickL. C.CrosslandJ. P.DawsonW. D. (1998). deer mice as laboratory animals.ILAR J.39322–330. 10.1093/ilar.39.4.322
81
JuanE.LevisS.PiniN.PolopJ.SteinmannA. R.ProvensalM. C. (2019). Mechanisms of hantavirus transmission in Oligoryzomys longicaudatus.Ecohealth16671–681. 10.1007/s10393-019-01454-y
82
KallioE. R.KlingstromJ.GustafssonE.ManniT.VaheriA.HenttonenH.et al (2006). Prolonged survival of Puumala hantavirus outside the host: evidence for indirect transmission via the environment.J. Gen. Virol.87(Pt 8), 2127–2134. 10.1099/vir.0.81643-0
83
KamrudK. I.SchmaljohnC. S. (1994). Expression strategy of the M genome segment of Hantaan virus.Virus Res.31109–121. 10.1016/0168-1702(94)90074-4
84
KariwaH.FujikiM.YoshimatsuK.ArikawaJ.TakashimaI.HashimotoN. (1998). Urine-associated horizontal transmission of Seoul virus among rats.Arch. Virol.143365–374. 10.1007/s007050050292
85
KatoH.TakeuchiO.SatoS.YoneyamaM.YamamotoM.MatsuiK.et al (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.Nature441101–105. 10.1038/nature04734
86
KawaiT.AkiraS. (2007). TLR signaling.Semin. Immunol.1924–32.
87
KeeneyG. L.Von WinterfeldtD. (2010). Identifying and structuring the objectives of terrorists.Risk Anal.301803–1816. 10.1111/j.1539-6924.2010.01472.x
88
KlempaB. (2009). Hantaviruses and climate change.Clin. Microbiol. Infect.15518–523. 10.1111/j.1469-0691.2009.02848.x
89
KlempaB. (2018). Reassortment events in the evolution of hantaviruses.Virus Genes54638–646. 10.1007/s11262-018-1590-z
90
KlingströmJ.PlyusninA.VaheriA.LundkvistA. (2002). Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques.J. Virol.76444–449. 10.1128/jvi.76.1.444-449.2002
91
KnustB.RollinP. E. (2013). Twenty-year summary of surveillance for human hantavirus infections, United States.Emerg. Infect. Dis.191934–1937. 10.3201/eid1912.131217
92
KrausA. A.PriemerC.HeiderH.KrugerD. H.UlrichR. (2005). Inactivation of Hantaan virus-containing samples for subsequent investigations outside biosafety level 3 facilities.Intervirology48255–261. 10.1159/000084603
93
KrugerD. H.SchonrichG.KlempaB. (2011). Human pathogenic hantaviruses and prevention of infection.Hum. Vaccin.7685–693. 10.4161/hv.7.6.15197
94
KrügerD. H.SchönrichG.KlempaB. (2011). Human pathogenic hantaviruses and prevention of infection.Hum Vaccin7685–693. 10.4161/hv.7.6.15197
95
KukkonenS. K.VaheriA.PlyusninA. (2005). L protein, the RNA-dependent RNA polymerase of hantaviruses.Arch. Virol.150533–556. 10.1007/s00705-004-0414-8
96
LameireN. (2014). Wars, disasters and kidneys.Acta Clin. Belg.69418–425. 10.1179/0001551214z.00000000087
97
LawrenceM.StembergerH.ZolderdoA.StruthersD.CookeS. (2015). The effects of modern war and military activities on biodiversity and the environment.Environ. Rev.23443–460. 10.1139/er-2015-0039
98
LeeH. W.LeeP. W.JohnsonK. M. (2004). Isolation of the etiologic agent of Korean hemorrhagic fever. 1978.J. Infect. Dis.1901711–1721. 10.1093/infdis/190.9.1711
99
LevineJ. R.PrescottJ.BrownK. S.BestS. M.EbiharaH.FeldmannH. (2010). Antagonism of type I interferon responses by new world hantaviruses.J. Virol.8411790–11801. 10.1128/jvi.00916-10
100
LiJ. L.LingJ. X.ChenL. J.WeiF.LuoF.LiuY. Y.et al (2013). An efficient method for isolation of Hantaan virus through serial passages in suckling mice.Intervirology56172–177. 10.1159/000345444
101
LiN.LuoF.ChenQ.ZhuN.WangH.XieL.et al (2019). IFN-λs inhibit Hantaan virus infection through the JAK-STAT pathway and expression of Mx2 protein.Genes Immun.20234–244. 10.1038/s41435-018-0028-x
102
LinX. D.GuoW. P.WangW.ZouY.HaoZ. Y.ZhouD. J.et al (2012). Migration of Norway rats resulted in the worldwide distribution of Seoul hantavirus today.J. Virol.86972–981. 10.1128/jvi.00725-11
103
LiuR.MaH.ShuJ.ZhangQ.HanM.LiuZ.et al (2019). Vaccines and therapeutics against Hantaviruses.Front. Microbiol.10:2989. 10.3389/fmicb.2019.02989
104
LlahS. T.MirS.SharifS.KhanS.MirM. A. (2018). Hantavirus induced cardiopulmonary syndrome: a public health concern.J. Med. Virol.901003–1009. 10.1002/jmv.25054
105
LõhmusM.JanseI.van de GootF.van RotterdamB. J. (2013). Rodents as potential couriers for bioterrorism agents.Biosecur. Bioterror.11S247–S257.
106
LonnerB. N.DouglassR. J.KuenziA. J.HughesK. (2008). Seroprevalence against Sin Nombre virus in resident and dispersing deer mice.Vector Borne Zoonotic Dis.8433–441. 10.7589/0090-3558-46.2.433
107
LundkvistA.ChengY.SjölanderK. B.NiklassonB.VaheriA.PlyusninA. (1997). Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment.J. Virol.719515–9523. 10.1128/jvi.71.12.9515-9523.1997
108
MackowE. R.DalrympleN. A.CimicaV.MatthysV.GorbunovaE.GavrilovskayaI. (2014). Hantavirus interferon regulation and virulence determinants.Virus Res.18765–71. 10.1016/j.virusres.2013.12.041
109
Mari SaezA.CamaraA.KouroumaF.SageM.MagassoubaN.Fichet-CalvetE. (2018). Rodent control to fight Lassa fever: evaluation and lessons learned from a 4-year study in Upper Guinea.PLoS Negl. Trop. Dis.12:e0006829. 10.1371/journal.pntd.0006829
110
MariënJ.BorremansB.KouroumaF.BafordayJ.RiegerT.GüntherS.et al (2019). Evaluation of rodent control to fight Lassa fever based on field data and mathematical modelling.Emerg. Microbes Infect.8640–649. 10.1080/22221751.2019.1605846
111
MarkoticA.LeDucJ. W.HlacaD.RabaticS.SarcevicA.DasicG.et al (1996). Hantaviruses are likely threat to NATO forces in Bosnia and Herzegovina and Croatia.Nat. Med.2269–270. 10.1038/nm0396-269
112
MartinT. L.BalserS. R.YoungG. S.LewisS. D. (2016). Cost and Effectiveness of commercially available nesting substrates for deer mice (Peromyscus maniculatus).J. Am. Assoc. Lab. Anim. Sci.55412–418.
113
MartinezV. P.BellomoC.San JuanJ.PinnaD.ForlenzaR.ElderM.et al (2005). Person-to-person transmission of Andes virus.Emerg. Infect. Dis.111848–1853. 10.3201/eid1112.050501
114
Martinez-ValdebenitoC.CalvoM.VialC.MansillaR.MarcoC.PalmaR. E.et al (2014). Person-to-person household and nosocomial transmission of andes hantavirus, Southern Chile, 2011.Emerg. Infect. Dis.201629–1636.
115
MatheusS.KallelH.MayenceC.BremandL.HouckeS.RoussetD. (2017). Hantavirus pulmonary syndrome caused by Maripa Virus in French Guiana, 2008-2016.Emerg. Infect. Dis.231722–1725. 10.3201/eid2310.170842
116
MatthysV.MackowE. R. (2012). Hantavirus regulation of type I interferon responses.Adv. Virol.2012:524024.
117
McKeeK. T.Jr.HugginsJ. W.TrahanC. J.MahlandtB. G. (1988). Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever.Antimicrob. Agents Chemother.321304–1309. 10.1128/aac.32.9.1304
118
McNabF.Mayer-BarberK.SherA.WackA.O’GarraA. (2015). Type I interferons in infectious disease.Nat. Rev. Immunol.1587–103. 10.1038/nri3787
119
MedinaR. A.Mirowsky-GarciaK.HuttJ.HjelleB. (2007). Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model.J. Gen. Virol.88(Pt 2), 493–505. 10.1099/vir.0.82459-0
120
MedinaR. A.Torres-PerezF.GalenoH.NavarreteM.VialP. A.PalmaR. E.et al (2009). Ecology, genetic diversity, and phylogeographic structure of andes virus in humans and rodents in Chile.J. Virol.832446–2459. 10.1128/jvi.01057-08
121
MeerburgB. G.BromF. W.KijlstraA. (2008). The ethics of rodent control.Pest. Manag. Sci.641205–1211.
122
MertzG. J.MiedzinskiL.GoadeD.PaviaA. T.HjelleB.HansbargerC. O.et al (2004). Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America.Clin. Infect. Dis.391307–1313. 10.1086/425007
123
MeyerR. F.MorseS. A. (2008). “Viruses and Bioterrorism,” in Encyclopedia of Virology, Third Edn, edsMahyB.W. J.Van RegenmortelM. H. V. (Oxford: Academic Press), 406–411. 10.1016/b978-012374410-4.00549-5
124
MirM. A. (2010). Hantaviruses.Clin. Lab. Med3067–91.
125
MirM. A.BrownB.HjelleB.DuranW. A.PanganibanA. T. (2006). Hantavirus N protein exhibits genus-specific recognition of the viral RNA panhandle.J. Virol.8011283–11292. 10.1128/jvi.00820-06
126
MirM. A.PanganibanA. T. (2004). Trimeric hantavirus nucleocapsid protein binds specifically to the viral RNA panhandle.J. Virol.788281–8288. 10.1128/jvi.78.15.8281-8288.2004
127
MirM. A.PanganibanA. T. (2005). The hantavirus nucleocapsid protein recognizes specific features of the viral RNA panhandle and is altered in conformation upon RNA binding.J. Virol.791824–1835. 10.1128/jvi.79.3.1824-1835.2005
128
MirM. A.PanganibanA. T. (2006a). Characterization of the RNA chaperone activity of hantavirus nucleocapsid protein.J. Virol.806276–6285. 10.1128/jvi.00147-06
129
MirM. A.PanganibanA. T. (2006b). The Bunyavirus nucleocapsid protein is an RNA chaperone: possible roles in viral RNA panhandle formation and genome replication.RNA12272–282. 10.1261/rna.2101906
130
MirM. A.SheemaS.HaseebA.HaqueA. (2010). Hantavirus nucleocapsid protein has distinct m7G cap- and RNA-binding sites.J. Biol. Chem.28511357–11368. 10.1074/jbc.m110.102459
131
MiroslavP. (2020). Bacillus anthracis as a biological warfare agent: infection, diagnosis and countermeasures.Bratisl. Lek. Listy121175–181. 10.4149/bll_2020_026
132
MittlerE.DieterleM. E.KleinfelterL. M.SloughM. M.ChandranK.JangraR. K. (2019). Hantavirus entry: perspectives and recent advances.Adv. Virus Res.104185–224. 10.1016/bs.aivir.2019.07.002
133
Montoya-RuizC.DiazF. J.RodasJ. D. (2014). Recent evidence of hantavirus circulation in the American tropic.Viruses61274–1293. 10.3390/v6031274
134
Munshi-SouthJ.RichardsonJ. L. (2017). Peromyscus transcriptomics: Understanding adaptation and gene expression plasticity within and between species of deer mice.Semin. Cell Dev. Biol.61131–139. 10.1016/j.semcdb.2016.08.011
135
MuranyiW.KehmR.BahrU.MullerS.HandermannM.DaraiG.et al (2004). Bovine aortic endothelial cells are susceptible to hantavirus infection; a new aspect in hantavirus ecology.Virology318112–122. 10.1016/j.virol.2003.09.006
136
MuyangwaM.MartynovaE. V.KhaiboullinaS. F.MorzunovS. P.RizvanovA. A. (2015). Hantaviral proteins: structure, functions, and role in Hantavirus infection.Front. Microbiol.6:1326. 10.3389/fmicb.2015.01326
137
NetskiD.ThranB. H.St. JeorS. C. (1999). Sin Nombre Virus Pathogenesis in Peromyscus maniculatus.J. Virol.73585–591. 10.1128/jvi.73.1.585-591.1999
138
NIAID (2018). US NIAID Emerging Infectious Diseases/Pathogens. Available online at: https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens(accessed March 30, 2020).
139
NicholS. T.SpiropoulouC. F.MorzunovS.RollinP. E.KsiazekT. G.FeldmannH.et al (1993). Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness.Science262914–917. 10.1126/science.8235615
140
NicolaM.AlsafiZ.SohrabiC.KerwanA.IosifidisC.AghaM.et al (2020). The socio-economic implications of the Coronavirus and COVID-19 pandemic: a review.Int. J. Surg.78185–193.
141
NiskanenS.JaaskelainenA.VapalahtiO.SironenY. (2019). Evaluation of Real-Time RT-PCR for Diagnostic Use in Detection of Puumala Virus.Viruses11:661. 10.3390/v11070661
142
OphinniY.InoueM.KotakiT.KameokaM. (2018). CRISPR/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures.Sci. Rep.8:7784.
143
PadulaP.FigueroaR.NavarreteM.PizarroE.CadizR.BellomoC.et al (2004). Transmission study of Andes Hantavirus infection in wild sigmodontine rodents.J. Virol.7811972–11979. 10.1128/jvi.78.21.11972-11979.2004
144
PanW.BianG.WangK.FengT.DaiJ. (2015). Effects of different doses of nucleocapsid protein from Hantaan Virus A9 strain on regulation of interferon signaling.Viral Immunol.28448–454. 10.1089/vim.2015.0004
145
ParkS. E. (2020). Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2, Coronavirus Disease-19).Clin. Exp. Pediatr.63119–124. 10.3345/cep.2020.00493
146
ParkesL. O.NguyenT. T.LongtinJ.BeaudoinM. C.Bestman-SmithJ.VinhD. C.et al (2016). A cluster of three cases of hantavirus pulmonary syndrome among canadian military personnel.Can. J. Infect. Dis. Med. Microbiol.2016:2757969.
147
PastorinoB.de LamballerieX.CharrelR. (2017). Biosafety and Biosecurity in European containment level 3 laboratories: focus on French recent progress and essential requirements.Front. Public Health5:121. 10.3389/fpubh.2017.00121
148
PizarroE.NavarreteM.MendezC.ZarorL.MansillaC.TapiaM.et al (2019). Immunocytochemical and ultrastructural evidence supporting that Andes Hantavirus (ANDV) is transmitted person-to-person through the respiratory and/or salivary pathways.Front. Microbiol.10:2992. 10.3389/fmicb.2019.02992
149
PlyusninA.VapalahtiO.VaheriA. (1996). Hantaviruses: genome structure, expression and evolution.J. Gen. Virol.77(Pt 11), 2677–2687. 10.1099/0022-1317-77-11-2677
150
PrescottJ.FeldmannH.SafronetzD. (2017). Amending Koch’s postulates for viral disease: When “growth in pure culture” leads to a loss of virulence.Antiviral Res.1371–5. 10.1016/j.antiviral.2016.11.002
151
PrescottJ.HallP.Acuna-RetamarM.YeC.WatheletM. G.EbiharaH.et al (2010). New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells.PLoS One5:e11159. 10.1371/journal.pone.0011159
152
QuetierF. (2016). The CRISPR-Cas9 technology: closer to the ultimate toolkit for targeted genome editing.Plant Sci.24265–76. 10.1016/j.plantsci.2015.09.003
153
RichardsonK. S.KuenziA.DouglassR. J.HartJ.CarverS. (2013). Human exposure to particulate matter potentially contaminated with sin nombre virus.Ecohealth10159–165. 10.1007/s10393-013-0830-x
154
RiquelmeR.RiosecoM. L.BastidasL.TrincadoD.RiquelmeM.LoyolaH.et al (2015). Hantavirus pulmonary syndrome, Southern Chile, 1995-2012.Emerg. Infect. Dis.21562–568.
155
Risteska-NejashmikjV.Ristikj-StomnaroskaD.BosevskaG.PapaA.StojkovskaS. (2019). Facing of family doctor with Hantavirus infection.Open Access Maced. J. Med. Sci.71660–1664. 10.3889/oamjms.2019.468
156
RizvanovA. A.KhaiboullinaS. F.St JeorS. (2004). Development of reassortant viruses between pathogenic Hantavirus strains.Virology327225–232. 10.1016/j.virol.2004.07.012
157
RodriguezL. L.OwensJ. H.PetersC. J.NicholS. T. (1998). Genetic reassortment among viruses causing hantavirus pulmonary syndrome.Virology24299–106. 10.1006/viro.1997.8990
158
RovidaF.PercivalleE.SarasiniA.ChichinoG.BaldantiF. (2013). Imported hantavirus cardiopulmonary syndrome in an Italian traveller returning from Cuba.New Microbiol.36103–105.
159
Sabino-SantosG.Jr.MaiaF. G. M.MartinsR. B.GagliardiT. B.SouzaW. M.MuylaertR. L.et al (2018). Natural infection of Neotropical bats with hantavirus in Brazil.Sci. Rep.8:9018.
160
SafronetzD.FalzaranoD.ScottD. P.FurutaY.FeldmannH.GowenB. B. (2013). Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome.Antimicrob. Agents Chemother.574673–4680. 10.1128/aac.00886-13
161
SafronetzD.HaddockE.FeldmannF.EbiharaH.FeldmannH. (2011). In vitro and in vivo activity of ribavirin against Andes virus infection.PLoS One6:e23560. 10.1371/journal.pone.0023560
162
SafronetzD.PrescottJ.FeldmannF.HaddockE.RosenkeR.OkumuraA.et al (2014). Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques.Proc. Natl. Acad. Sci. U.S.A.1117114–7119. 10.1073/pnas.1401998111
163
SchmaljohnC. (2009). Vaccines for Hantaviruses.Vaccine27(Suppl. 4), D61–D64.
164
SchmaljohnC.HjelleB. (1997). Hantaviruses: a global disease problem.Emerg. Infect. Dis.395–104. 10.3201/eid0302.970202
165
SchmaljohnC. S.HastyS. E.DalrympleJ. M. (1992). Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome.Vaccine1010–13. 10.1016/0264-410x(92)90412-d
166
SchmaljohnC. S.SpikK. W.HooperJ. W. (2014). DNA vaccines for HFRS: laboratory and clinical studies.Virus Res.18791–96. 10.1016/j.virusres.2013.12.020
167
SenG. C.SarkarS. N. (2005). Transcriptional signaling by double-stranded RNA: role of TLR3.Cytokine Growth Factor Rev.161–14. 10.1016/j.cytogfr.2005.01.006
168
SetoT.TkachenkoE. A.MorozovV. G.TanikawaY.KolominovS. I.BelovS. N.et al (2011). An efficient in vivo method for the isolation of Puumala virus in Syrian hamsters and the characterization of the isolates from Russia.J. Virol. Methods17317–23. 10.1016/j.jviromet.2010.12.019
169
SongJ. Y.WooH. J.CheongH. J.NohJ. Y.BaekL. J.KimW. J. (2016). Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax) in healthy adults.Vaccine341289–1295. 10.1016/j.vaccine.2016.01.031
170
SpiropoulouC. F.MorzunovS.FeldmannH.SanchezA.PetersC. J.NicholS. T. (1994). Genome structure and variability of a virus causing hantavirus pulmonary syndrome.Virology200715–723. 10.1006/viro.1994.1235
171
TaylorS. L.Frias-StaheliN.García-SastreA.SchmaljohnC. S. (2009). Hantaan virus nucleocapsid protein binds to importin alpha proteins and inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappa B.J. Virol.831271–1279. 10.1128/jvi.00986-08
172
ThaoT. T. N.LabroussaaF.EbertN.V’kovskiP.StalderH.PortmannJ.et al (2020). Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform.Nature582561–565.
173
TianD.ZhengT. (2014). Comparison and analysis of biological agent category lists based on biosafety and biodefense.PLoS One9:e101163. 10.1371/journal.pone.0101163
174
ToroJ.VegaJ. D.KhanA. S.MillsJ. N.PadulaP.TerryW.et al (1998). An outbreak of Hantavirus pulmonary syndrome, Chile, 1997.Emerg. Infect. Dis.4687–694.
175
VaheriA.HenttonenH.VoutilainenL.MustonenJ.SironenT.VapalahtiO. (2013). Hantavirus infections in Europe and their impact on public health.Rev. Med. Virol.2335–49. 10.1002/rmv.1722
176
VaheriA.VapalahtiO.PlyusninA. (2008). How to diagnose Hantavirus infections and detect them in rodents and insectivores.Rev. Med. Virol.18277–288. 10.1002/rmv.581
177
Van LoockF.ThomasI.ClementJ.GhoosS.ColsonP. (1999). A case-control study after a hantavirus infection outbreak in the south of Belgium: Who is at risk?Clin. Infect. Dis.28834–839. 10.1086/515196
178
VapalahtiK.PaunioM.Brummer-KorvenkontioM.VaheriA.VapalahtiO. (1999). Puumala virus infections in Finland: increased occupational risk for farmers.Am. J. Epidemiol.1491142–1151. 10.1093/oxfordjournals.aje.a009769
179
VapalahtiO.MustonenJ.LundkvistA.HenttonenH.PlyusninA.VaheriA. (2003). Hantavirus infections in Europe.Lancet Infect. Dis.3653–661.
180
VergoteV.LaenenL.VanmechelenB.Van RanstM.VerbekenE.HooperJ. W.et al (2017). A lethal disease model for New World hantaviruses using immunosuppressed Syrian hamsters.PLoS Negl. Trop. Dis.11:e0006042. 10.1371/journal.pntd.0006042
181
Vigueras-GalvanA. L.Lopez-PerezA. M.Garcia-PenaG. E.Rico-ChavezO.Sarmiento-SilvaR. E.SuzanG. (2019). Current situation and perspectives on Hantaviruses in Mexico.Viruses11:642. 10.3390/v11070642
182
WalteeD.LonnerB. N.KuenziA. J.DouglassR. J. (2009). Seasonal dispersal patterns of sylvan deer mice (Peromyscus maniculatus) within Montana rangelands.J. Wildl. Dis.45998–1007. 10.7589/0090-3558-45.4.998
183
WangX.ShenW.QinY.YingL.LiH.LuJ.et al (2020). A case-control study on the risk factors for hemorrhagic fever with renal syndrome.BMC Infect. Dis.20:103. 10.1186/s12879-020-4830-5
184
WarnerB. M.SteinD. R.GriffinB. D.TierneyK.LeungA.SloanA.et al (2019a). Development and Characterization of a Sin Nombre Virus Transmission Model in Peromyscus maniculatus.Viruses11:183.
185
WarnerB. M.SteinD. R.JangraR. K.SloughM. M.SrogaP.SloanA.et al (2019b). Vesicular stomatitis virus-based vaccines provide cross-protection against Andes and Sin Nombre Viruses.Viruses11:645.
186
WatsonD. C.SargianouM.PapaA.ChraP.StarakisI.PanosG. (2014). Epidemiology of Hantavirus infections in humans: a comprehensive, global overview.Crit. Rev. Microbiol.40261–272.
187
WheelisM.CasagrandeR.MaddenL. (2009). Biological attack on agriculture: low-tech, high-impact bioterrorism.Bioscience52569–576.
188
WhiteS. M. (2002). Chemical and biological weapons. Implications for anaesthesia and intensive care.Br. J. Anaesth.89306–324.
189
WilliamsM.SizemoreD. C. (2020). Biologic, Chemical, and Radiation Terrorism Review.Treasure Island, FL: StatPearls Publishing LLC.
190
WitkowskiP. T.PerleyC. C.BrocatoR. L.HooperJ. W.JurgensenC.SchulzkeJ. D.et al (2017). Gastrointestinal tract as entry route for Hantavirus infection.Front. Microbiol.8:1721. 10.3389/fmicb.2017.01721
191
WoolhouseM. E.BrierleyL.McCafferyC.LycettS. (2016). Assessing the Epidemic Potential of RNA and DNA Viruses.Emerg. Infect. Dis.222037–2044.
192
YanagiharaR.AmyxH. L.GajdusekD. C. (1985). Experimental infection with Puumala virus, the etiologic agent of nephropathia epidemica, in bank voles (Clethrionomys glareolus).J. Virol.5534–38.
193
YiY.ParkH.JungJ. (2018). Effectiveness of inactivated Hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome.Kidney Res. Clin. Pract.37366–372.
194
YingQ.MaT.ChengL.ZhangX.TruaxA. D.MaR.et al (2016). Construction and immunological characterization of CD40L or GM-CSF incorporated Hantaan virus like particle.Oncotarget763488–63503.
195
ZakiS. R.GreerP. W.CoffieldL. M.GoldsmithC. S.NolteK. B.FoucarK.et al (1995). Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease.Am. J. Pathol.146552–579.
196
ZhangY. Z.ZouY.FuZ. F.PlyusninA. (2010). Hantavirus infections in humans and animals, China.Emerg. Infect. Dis.161195–1203.
197
ZhaoJ.AzadM. B.BertrandE. M.BurtonC.CrooksV. A.DawsonJ.et al (2020). Canadian Science Meets Parliament: building relationships between scientists and policymakers.Sci. Public Policy47298–298.
Summary
Keywords
hantavirus, Sin Nombre Virus, Andes Virus, biodefense, bioterrorism, viral pandemic, hantavirus cardiopulmonary syndrome, transmission
Citation
D’Souza MH and Patel TR (2020) Biodefense Implications of New-World Hantaviruses. Front. Bioeng. Biotechnol. 8:925. doi: 10.3389/fbioe.2020.00925
Received
26 May 2020
Accepted
17 July 2020
Published
07 August 2020
Volume
8 - 2020
Edited by
Stephen Allen Morse, Centers for Disease Control and Prevention (CDC), United States
Reviewed by
Segaran P. Pillai, United States Department of Homeland Security, United States; Wei Zou, University of Michigan, United States
Updates

Check for updates
Copyright
© 2020 D’Souza and Patel.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Trushar R. Patel, trushar.patel@uleth.ca
†ORCID: Michael Hilary D’Souza, orcid.org/0000-0001-8709-4019; Trushar R. Patel, orcid.org/0000-0003-0627-2923
This article was submitted to Biosafety and Biosecurity, a section of the journal Frontiers in Bioengineering and Biotechnology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.